Cart
sales@molnova.com
Lisaftoclax
CAS No. 2180923-05-9
Lisaftoclax ( Bcl-2/Bcl-xl inhibitor 1; APG-2575 )
Catalog No. M26069 CAS No. 2180923-05-9
Bcl-2/Bcl-xl inhibitor 1 is a dual Bcl-2 and Bcl-xl inhibitor (IC50s: 2 nM and 5.9 nM for Bcl-2 and Bcl-xl) with anti-tumor activity. It is extracted from patent WO2018027097A1.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 621 | Get Quote |
|
| 10MG | 893 | Get Quote |
|
| 25MG | 1323 | Get Quote |
|
| 50MG | 1782 | Get Quote |
|
| 100MG | 2412 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLisaftoclax
-
NoteResearch use only, not for human use.
-
Brief DescriptionBcl-2/Bcl-xl inhibitor 1 is a dual Bcl-2 and Bcl-xl inhibitor (IC50s: 2 nM and 5.9 nM for Bcl-2 and Bcl-xl) with anti-tumor activity. It is extracted from patent WO2018027097A1.
-
DescriptionBcl-2/Bcl-xl inhibitor 1 is a dual Bcl-2 and Bcl-xl inhibitor (IC50s: 2 nM and 5.9 nM for Bcl-2 and Bcl-xl) with anti-tumor activity. It is extracted from patent WO2018027097A1.(In Vitro):Lisaftoclax shows IC50s of 5.5 nM and 6.4 nM in Bcl-2 dependent RS4 11 cells and Bcl-xl dependent Molm 13 cells.
-
SynonymsBcl-2/Bcl-xl inhibitor 1; APG-2575
-
PathwayAngiogenesis
-
TargetBcl-2
-
RecptorE3 ligase ligand-linker conjugate
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2180923-05-9
-
Formula Weight882.4
-
Molecular FormulaC45H48ClN7O8S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES[O-][N+](=O)c1cc(ccc1NC[C@H]1COCCO1)S(=O)(=O)NC(=O)c1ccc(cc1Oc1cnc2[nH]ccc2c1)N1CCN(CC2=C(CC3(CCC3)CC2)c2ccc(Cl)cc2)CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
17-Hydroxy sprengeri...
17-Hydroxy sprengerinin C is a glycoside compound isolated from rhizomes of Polygonatum sibiricum with stronger anticancer activities.
-
Bcl-xL antagonist 2
Bcl-xL antagonist 2 is an effective and selective antagonist of Bcl-xL with an IC50 of 91 nM and a Ki of 65 nM. Bcl-xL antagonist 2 induces apoptosis in cancer cells and can be used in studies about chronic lymphocytic leukemia and non-Hodgkin’s lymphoma.
-
(-) BI97D6
(-) BI97D6 (BI112D1) is a potent, pan-active inhibitor of Bcl-2 family proteins with IC50 of 76, 31, 25, and 122 nM for Bcl-xL, Bcl-2, Mcl-1, and Bfl-1, respectively.
